Drawing for HARROW HEALTH | INC.

USPTO serial 88243153

HARROW HEALTH | INC.

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CHIANG, TIFFANY YOUNG
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HARROW HEALTH | INC.?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Antony M. Novom

ANTONY M. NOVOM WAGENKNECHT IP LAW GROUP PC12396 WORLD TRADE DRIVE, SUITE 312SAN DIEGO, CA 92128UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical compositions for ophthalmological use, for anesthesiological applications, for treating fibrotic diseases, for treating male sexual disorders, for treating skin disorders, for treating kidney stones, for treating nail disorders, for treating autoimmune diseases and cancer, and for treating bleedingACTIVE—
036Financial adviceACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Feb 10, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 10, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 6, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 9, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 14, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 14, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 24, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 1, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 27, 2019DOCKASSIGNED TO EXAMINER—
Mar 27, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Mar 27, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 27, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 27, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 6, 2019CEPECOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED—
Feb 6, 2019ALIEASSIGNED TO LIE—
Feb 5, 2019GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Feb 5, 2019GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Feb 5, 2019CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Jan 30, 2019DOCKASSIGNED TO EXAMINER—
Jan 19, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jan 18, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 31, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance